News | December 20, 2011

Adult Stem Cell Patients Continue to See Cardiac Improvement Years After Treatment


December 20, 2011 –– Howie Lindeman was facing the loss of his career and Neim Malo wasn’t supposed to see 2011. They were each treated for heart disease years ago using their own stem cells to repair their damaged heart tissue. Several years following treatment from Regenocyte, both men continue to see improvement in their condition and quality of life.

Howie Lindeman, 60, had a heart attack at 39 years old that severely damaged his heart. He went through several procedures including having stents placed in his arteries and his physicians were considering open-heart surgery for a quintuple bypass. He was in constant pain and struggled to walk just 25 feet, but when Zannos G. Grekos, M.D., MAAC, FACC, chief medical officer of Regenocyte and a Florida-based pioneer in the field of adult stem cell therapy suggested he have the Regenocyte adult stem cell procedure, he jumped at the opportunity. A normal ejection fraction (EF) is over 50 percent and Lindeman’s was down to a dangerous 22 percent before the adult stem cell procedure. Shortly after receiving treatment, his EF improved to a near-normal 47 percent, and is now at a stable 54 percent.

Neim Malo, 54, suffered a heart attack at 47 years old. He had three stents put in and was told by doctors that he would only live five more years. He refused to accept such a grim fate, so he searched for alternative treatment and found adult stem cell therapy. Malo’s EF was at 28 percent when he received adult stem cell treatment in 2006 and since then, his heart function has improved to 50 percent.

“I have more energy than ever,” said Malo. “You can still find me in my restaurant everyday outpacing people half my age. I’ve lived beyond those five years and will continue to prove my former doctors wrong.”

Lindeman and Malo now participate in Regenocyte seminars to share their experiences with attendees who are considering the treatment for themselves or their loved ones. In his presentation about the Regenocyte procedure, Grekos describes how blood is extracted from the patient and sent on to a laboratory where the patient’s stem cells are removed.

“The lab provides a key step in the Regenocyte process,” Grekos explained. “The lab extracts the stem cells from the blood and activates them into millions of adult stem cells while ‘educating’ them to assist the exact organ that needs treatment.”

About a week after the blood arrives at the laboratory, the adult stem cells are shipped to a hospital at an international location and the patient has already been admitted.

In this groundbreaking treatment, cardiologist inserted a catheter into Lindeman and Malo’s hearts. Over the next 20 minutes, about 30 separate injections of adult stem cells were introduced into the damaged part of their hearts. The process of tissue repair began almost immediately.

Patients remain in the hospital overnight for observation, and are typically discharged the next day. Grekos continues to have regular appointments with patients to monitor their progress and measure their results.

“We continue to see remarkable results from adult stem cell treatment,” said Grekos. “Successes like those we’ve seen with Howie and Neim are not uncommon and show significant promise for diseases in other organs.”

“I have a high-stress, high-energy job that I absolutely love,” says Lindeman. “The Regenocyte adult stem cell treatment has allowed me to continue my career and enjoy the active lifestyle I thought I had lost for good. I’m a new person and I continue to feel better every day.”

Grekos and the Regenocyte medical team continue to research the impact of adult stem cell therapy on heart disease.

For more information:

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
News | Cardiac Diagnostics| September 12, 2017
Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack,...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
News | Pharmaceuticals| September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Overlay Init